These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 35276329)

  • 1. Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial.
    Danese S; Sands BE; Abreu MT; O'Brien CD; Bravatà I; Nazar M; Miao Y; Wang Y; Rowbotham D; Leong RWL; Arasaradnam RP; Afif W; Marano C
    Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2858-2867.e5. PubMed ID: 35276329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sands BE; Sandborn WJ; Panaccione R; O'Brien CD; Zhang H; Johanns J; Adedokun OJ; Li K; Peyrin-Biroulet L; Van Assche G; Danese S; Targan S; Abreu MT; Hisamatsu T; Szapary P; Marano C;
    N Engl J Med; 2019 Sep; 381(13):1201-1214. PubMed ID: 31553833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
    Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension.
    Abreu MT; Rowbotham DS; Danese S; Sandborn WJ; Miao Y; Zhang H; Tikhonov I; Panaccione R; Hisamatsu T; Scherl EJ; Leong RW; Arasaradnam RP; Afif W; Peyrin-Biroulet L; Sands BE; Marano C
    J Crohns Colitis; 2022 Aug; 16(8):1222-1234. PubMed ID: 35239968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
    Panaccione R; Danese S; Sandborn WJ; O'Brien CD; Zhou Y; Zhang H; Adedokun OJ; Tikhonov I; Targan S; Abreu MT; Hisamatsu T; Scherl EJ; Leong RW; Rowbotham DS; Arasaradnam RP; Sands BE; Marano C
    Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1658-1675. PubMed ID: 33086438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
    Feagan BG; Danese S; Loftus EV; Vermeire S; Schreiber S; Ritter T; Fogel R; Mehta R; Nijhawan S; Kempiński R; Filip R; Hospodarskyy I; Seidler U; Seibold F; Beales ILP; Kim HJ; McNally J; Yun C; Zhao S; Liu X; Hsueh CH; Tasset C; Besuyen R; Watanabe M; Sandborn WJ; Rogler G; Hibi T; Peyrin-Biroulet L
    Lancet; 2021 Jun; 397(10292):2372-2384. PubMed ID: 34090625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis.
    Li K; Marano C; Zhang H; Yang F; Sandborn WJ; Sands BE; Feagan BG; Rubin DT; Peyrin-Biroulet L; Friedman JR; De Hertogh G
    Gastroenterology; 2020 Dec; 159(6):2052-2064. PubMed ID: 32853634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders.
    Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W; Narula N
    Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3387-3396.e1. PubMed ID: 37391059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment.
    Loftus EV; Colombel JF; Takeuchi K; Gao X; Panaccione R; Danese S; Dubinsky M; Schreiber S; Ilo D; Finney-Hayward T; Zhou W; Phillips C; Gonzalez YS; Shu L; Yao X; Zhou Q; Vermeire S
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2347-2358.e6. PubMed ID: 36464141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study.
    Afif W; Arasaradnam RP; Abreu MT; Danese S; Sandborn WJ; Miao Y; Zhang H; Panaccione R; Hisamatsu T; Scherl EJ; Leong RW; Rowbotham DS; Peyrin-Biroulet L; Sands BE; Marano C
    Am J Gastroenterol; 2024 May; 119(5):910-921. PubMed ID: 38095692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial.
    Danese S; Ferrante M; Feagan BG; Peyrin-Biroulet L; Hibi T; Sandborn WJ; Schreiber S; Ritter T; Loftus EV; Rogler G; Oortwijn A; Yun C; Le Brun FO; Dinoso J; Hsieh J; Vermeire S
    Am J Gastroenterol; 2023 Jan; 118(1):138-147. PubMed ID: 36113491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
    Peyrin-Biroulet L; Allegretti JR; Rubin DT; Bressler B; Germinaro M; Huang KG; Shipitofsky N; Zhang H; Wilson R; Han C; Feagan BG; Sandborn WJ; Panés J; Hisamatsu T; Lichtenstein GR; Sands BE; Dignass A;
    Gastroenterology; 2023 Dec; 165(6):1443-1457. PubMed ID: 37659673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using Computer Vision to Improve Endoscopic Disease Quantification in Therapeutic Clinical Trials of Ulcerative Colitis.
    Stidham RW; Cai L; Cheng S; Rajaei F; Hiatt T; Wittrup E; Rice MD; Bishu S; Wehkamp J; Schultz W; Khan N; Stojmirovic A; Ghanem LR; Najarian K
    Gastroenterology; 2024 Jan; 166(1):155-167.e2. PubMed ID: 37832924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.
    Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Feagan BG; Hibi T; Tuttle JL; Klekotka P; Friedrich S; Durante M; Morgan-Cox M; Laskowski J; Schmitz J; D'Haens GR
    Gastroenterology; 2020 Feb; 158(3):537-549.e10. PubMed ID: 31493397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis.
    Danese S; Neurath MF; Kopoń A; Zakko SF; Simmons TC; Fogel R; Siegel CA; Panaccione R; Zhan X; Usiskin K; Chitkara D
    Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2526-2534.e9. PubMed ID: 31926340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis.
    Ochsenkühn T; Tillack C; Szokodi D; Janelidze S; Schnitzler F
    United European Gastroenterol J; 2020 Feb; 8(1):91-98. PubMed ID: 32213052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Peyrin-Biroulet L; Zhang J; Chiorean M; Vermeire S; Lee SD; Kühbacher T; Yacyshyn B; Cabell CH; Naik SU; Klassen P; Panés J
    Gastroenterology; 2020 Feb; 158(3):550-561. PubMed ID: 31711921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of Placebo Induction Response and Remission in Ulcerative Colitis.
    Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W; Narula N
    Clin Gastroenterol Hepatol; 2023 Apr; 21(4):1050-1060.e9. PubMed ID: 36029969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
    Danese S; Colombel JF; Lukas M; Gisbert JP; D'Haens G; Hayee B; Panaccione R; Kim HS; Reinisch W; Tyrrell H; Oh YS; Tole S; Chai A; Chamberlain-James K; Tang MT; Schreiber S;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):118-127. PubMed ID: 34798038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.